November 1, 2010 | Last week Pacific Biosciences raised $200 million through its IPO, a number in the middle of its expected range. On the first day of trading, shares rose by 44 cents. Analysts view the success as further evidence that investors are looking favorably on life sciences tools. (See Xconomy). The IPO was also good news for Complete Genomics, which released an amended IPO prospectus after PacBio went public raising its self valuation from $6.85/share to $12 to $14/share. (See Wall Street Journal Blog).